MedTrace Logo

Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy

NCT05662800 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2023-04-19

No results posted yet for this study

Summary

The aim of the study is to assess the prevalence of peanut, tree nuts, and sesame allergy in Polish children at high risk of food allergy. Additionally, the timing of the development of peanut, tree nuts and sesame allergy in the first three years of life in a high-risk population will be assessed.

Conditions

Interventions

DIAGNOSTIC_TEST

Assessment of peanut, tree nuts and sesame allergy

Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste. Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9). Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests.

Sponsors & Collaborators

  • Nutricia Foundation

    collaborator OTHER

  • Thermo Fisher Scientific, Inc

    collaborator INDUSTRY

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Marek Kulus, MD, Prof. · Medical University of Warsaw

Eligibility

Min Age
4 Months
Max Age
36 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662800 on ClinicalTrials.gov